Adaptive Biotechnologies
ADPT
223 hedge funds and large institutions have $1.01B invested in Adaptive Biotechnologies in 2022 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 85 increasing their positions, 71 reducing their positions, and 26 closing their positions.
3,132% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $358K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
20% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 71
8% more capital invested
Capital invested by funds: $931M → $1.01B (+$76.3M)
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
0.57% more ownership
Funds ownership: 91.67% → 92.24% (+0.57%)
1% less funds holding
Funds holding: 226 → 223 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.5M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$4M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$4M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.69M |
| 5 |
Barclays
London,
United Kingdom
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.79M |
| 2 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
-$4.72M |
| 3 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$4.43M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.56M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$2.49M |
ADPT Hedge Fund Activity: Q4 2022 in Review
223 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2022, worth a combined $1.01B — up 8.2% from $931M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ADPT positions and 26 closed out — a net gain of 1 holder — while 85 added to existing stakes and 71 trimmed.
The largest buyer was BlackRock, adding an estimated $17.5M. The largest seller was Goldman Sachs, cutting an estimated $4.79M.
- 223 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2022, down from 226 in Q3 2022.
- Funds reported $1.01B of Adaptive Biotechnologies stock for Q4 2022, up 8.2% quarter-over-quarter.
- 27 funds opened new Adaptive Biotechnologies positions in Q4 2022 and 26 closed out, a net change of +1 holder.
- The largest Adaptive Biotechnologies buyer in Q4 2022 was BlackRock, an estimated $17.5M added.
- The largest Adaptive Biotechnologies seller in Q4 2022 was Goldman Sachs, an estimated $4.79M sold.
Based on aggregated 13F filings for Q4 2022.